Finance

Beta
Lists
EMCURE:NSE
Emcure Pharmaceuticals Ltd
₹1,696.00
-0.49%
(-8.40) 1D
Jun 3, 3:30:04 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for EMCURE...
Open
₹1,718.00
High
₹1,723.90
Low
₹1,690.80
Mkt. cap
321.66B
Avg. vol.
269.06K
Volume
79.59K
P/E ratio
34.78
52-wk high
₹1,830.00
52-wk low
₹1,228.90
EPS
₹48.77
No. of employees
7K
Open
₹1,718.00
High
₹1,723.90
Low
₹1,690.80
Mkt. cap
321.66B
Avg. vol.
269.06K
Volume
79.59K
P/E ratio
34.78
52-wk high
₹1,830.00
52-wk low
₹1,228.90
EPS
₹48.77
No. of employees
7K
News stories
From sources across the web
Profile
Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals. Wikipedia
About Emcure Pharmaceuticals Ltd
CEOSatish Ramanlal Mehta
Employees6.73K
FoundedApr 16, 1981
Headquarters-
SectorPharmaceutical industry
Websiteemcure.com
Last report
May 5, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
₹14.70 / ₹14.70
+0.00%beat
Revenue / Est. (INR)
24.70B / 24.20B
+2.06%beat
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
21.01B
22.70B
23.63B
24.70B
Cost of goods sold
8.02B
8.90B
9.62B
10.03B
Cost of revenue
8.02B
8.90B
9.62B
10.03B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.93B
3.85B
3.87B
3.87B
Operating expense
9.94B
10.46B
10.46B
10.87B
Total operating expenses
17.96B
19.35B
20.08B
20.90B
Operating income
3.04B
3.34B
3.55B
3.79B
Other non operating income
36.96M
31.23M
18.53M
39.92M
EBT including unusual items
2.91B
3.41B
3.14B
3.41B
EBT excluding unusual items
2.94B
3.41B
3.52B
3.74B
Income tax expense
759.65M
900.47M
824.22M
974.40M
Effective tax rate
26.13%
26.37%
26.27%
28.56%
Other operating expenses
5.01B
5.57B
5.54B
5.94B
Net income
2.07B
2.43B
2.31B
2.43B
Net profit margin
9.85%
10.73%
9.75%
9.86%
Earnings per share
11.06
12.85
13.67
14.70
Interest and investment income
-
-
-
-
Interest expense
-267.55M
-325.42M
-379.75M
-464.01M
Net interest expenses
-267.55M
-325.42M
-379.75M
-464.01M
Depreciation and amortization charges
994.56M
1.05B
1.05B
1.06B
EBITDA
3.86B
4.37B
4.37B
4.83B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer